A randomized phase III international trial presented at the fourth annual Genitourinary Cancers Symposium, being held February 2-4, 2012, at the San Francisco Marriott Marquis in San Francisco, CA, USA, shows for the first time that an investigational oral drug that halts androgen signaling significantly improves overall survival in patients with metastatic castration-resistant prostate cancer (CRPC).…
Feb 02, 12 03:30PM
|
0 comments
Contributor
More from this contributor
- Blinatumomab Achieved High Rate ...
- Fidaxomicin Offers Faster Diarrh...
- Rilotumumab Moves into Phase III...
- Study Shows ImmunoSEQ Assay Sign...
Comments
To add a comment to the original post, click here.
You must be signed in to post a comment.
Sign in nowThere are no comments for this post.